WHWK Whitehawk Therapeutics Inc.
Price (delayed)
$1.7
Market cap
$79.53M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.36
Enterprise value
$51.7M
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is
Highlights
The debt has contracted by 34% YoY and by 12% from the previous quarter
Whitehawk Therapeutics's revenue has increased by 7% YoY and by 3.6% from the previous quarter
The company's EPS fell by 3.5% QoQ but it rose by 3.3% YoY
The company's net income fell by 3.2% QoQ but it rose by 3.2% YoY
The company's equity has shrunk by 50% YoY and by 24% QoQ
WHWK's quick ratio is down by 29% since the previous quarter and by 28% year-on-year
Key stats
What are the main financial stats of WHWK
Market
Valuations
Earnings
Shares outstanding
46.78M
Market cap
$79.53M
Enterprise value
$51.7M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.8
Price to sales (P/S)
1.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.99
Revenue
$25.98M
Gross profit
$22.96M
Operating income
-$67.46M
Net income
-$63.69M
EBIT
-$63.54M
EBITDA
-$62.88M
Free cash flow
-$61.2M
Per share
Balance sheet
Liquidity
EPS
-$2.36
EPS diluted
-$2.36
Free cash flow per share
-$2.26
Book value per share
$2.13
Revenue per share
$0.96
TBVPS
$2.6
Total assets
$70.32M
Total liabilities
$17.84M
Debt
$833,000
Equity
$52.48M
Working capital
$44.21M
Debt to equity
0.02
Current ratio
3.59
Quick ratio
3.11
Net debt/EBITDA
0.44
Margins
Efficiency
Dividend
EBITDA margin
-242%
Gross margin
88.4%
Net margin
-245.1%
Operating margin
-259.6%
Return on assets
-69.1%
Return on equity
-87.7%
Return on invested capital
-176.9%
Return on capital employed
-119.3%
Return on sales
-244.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
WHWK stock price
How has the Whitehawk Therapeutics stock price performed over time
Intraday
0%
1 week
-11.46%
1 month
-33.59%
1 year
-22.02%
YTD
-46.12%
QTD
-4.49%
Financial performance
How have Whitehawk Therapeutics's revenue and profit performed over time
Revenue
$25.98M
Gross profit
$22.96M
Operating income
-$67.46M
Net income
-$63.69M
Gross margin
88.4%
Net margin
-245.1%
The operating margin rose by 12% YoY
The net margin has grown by 9% YoY
Whitehawk Therapeutics's revenue has increased by 7% YoY and by 3.6% from the previous quarter
The company's gross profit rose by 7% YoY and by 4.8% QoQ
Growth
What is Whitehawk Therapeutics's growth rate over time
Valuation
What is Whitehawk Therapeutics stock price valuation
P/E
N/A
P/B
0.8
P/S
1.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.99
The company's EPS fell by 3.5% QoQ but it rose by 3.3% YoY
The company's equity has shrunk by 50% YoY and by 24% QoQ
WHWK's price to book (P/B) is 47% less than its 5-year quarterly average of 1.5
The price to sales (P/S) is 93% less than the 5-year quarterly average of 24.0 and 29% less than the last 4 quarters average of 2.5
Whitehawk Therapeutics's revenue has increased by 7% YoY and by 3.6% from the previous quarter
Efficiency
How efficient is Whitehawk Therapeutics business performance
The return on invested capital has dropped by 94% year-on-year and by 17% since the previous quarter
The company's return on equity has shrunk by 67% YoY and by 22% QoQ
The return on assets has dropped by 56% year-on-year and by 21% since the previous quarter
The company's return on sales rose by 9% YoY
Dividends
What is WHWK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for WHWK.
Financial health
How did Whitehawk Therapeutics financials performed over time
Whitehawk Therapeutics's total assets has decreased by 47% YoY and by 18% QoQ
The total liabilities fell by 34% YoY but it rose by 6% QoQ
The debt is 98% less than the equity
The debt to equity has surged by 100% since the previous quarter and by 100% year-on-year
The company's equity has shrunk by 50% YoY and by 24% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.